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Abstract. Purpose: To investigate the in vitro binding
properties of a novel radiolabelled bombesin analogue,
177Lu-AMBA, in human neoplastic and non-neoplastic
tissues selected for their expression of the bombesin
receptor subtypes GRP-R, NMB-R and BRS-3.
Methods: In vitro receptor autoradiography was performed
in cancers expressing the various bombesin receptor
subtypes. The novel radioligand 177Lu-AMBA was used
and compared with established bombesin radioligands
such as 125I-Tyr4-bombesin and 125I-[D-Tyr6,β-Ala11,
Phe13,Nle14]-bombesin(6–14). In vitro incidence of detec-
tion of each of the three bombesin receptor subtypes was
evaluated in each tumour.
Results: 177Lu-AMBA identified all GRP-R-expressing
tumours, such as prostatic, mammary and renal cell
carcinomas as well as gastrointestinal stromal tumours.
177Lu-AMBA also identified all NMB-expressing tumours,
but did not detect BRS-3-expressing tumours or BRS-3-
expressing pancreatic islets. GRP-R-expressing peritumour-
al vessels were heavily labelled with 177Lu-AMBA. In
contrast to the strongly GRP-R-positive mouse pancreas,
the human pancreas was not labelled with 177Lu-AMBA
unless chronic pancreatitis was diagnosed. In general, the
sensitivity was slightly better with 177Lu-AMBA than with
the conventional bombesin radioligands.
Conclusion: The present in vitro study suggests that 177Lu-
AMBA may be a very useful in vivo targeting agent for
GRP-R-expressing tumours, NMB-R-expressing tumours
and GRP-R-expressing neoangiogenic vessels.
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Introduction
Peptide hormones and their receptors not only are very
important physiological regulators but also are becoming
increasingly relevant in tumour management: many ma-
lignant human tumours overexpress various peptide hor-
mone receptors, which can be used for in vivo tumour
targeting [1]. For instance, the high expression of somato-
statin receptors in gastroenteropancreatic neuroendocrine
tumours allows highly effective somatostatin receptor
targeted tumour imaging and therapy using radiolabelled
somatostatin analogues [2–4].
Recently, other peptides and their receptors have
attracted increasing interest, such as cholecystokinin, neu-
rotensin and bombesin receptors [1]. Bombesin receptors
are of particular interest, since widely occurring tumours
such as prostate and breast cancers often express bombesin
receptors [5, 6]. Moreover, it has also been reported that
radiolabelled bombesin analogues can successfully image
these tumours in vivo [7, 8]. Finally, a large number of
suitable radiopharmaceuticals have been synthesised and
characterised for this purpose [9–11]. One of the most recent
and most extensively characterised radiopharmaceuticals
of this type is 177Lu-AMBA [12]. The unlabelled AMBA
(DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-
NH2) binds with high affinity to gastrin-releasing peptide
(GRP) and neuromedin B (NMB) receptors, while it has no
affinity for BRS-3 receptors [12]. It has an excellent
pharmacokinetic profile [12] and has been found to inhibit
tumour growth in PC3 tumour-bearing mice [12]. This
compound is presently in phase I clinical trials.
The aim of the present study was to investigate the in
vitro binding characteristics of the novel radiolabelled
bombesin analogue 177Lu-AMBA, using a selection of
human tissues expressing the various bombesin receptors.
The method used for this purpose was bombesin receptor
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autoradiography, as described previously [13]. The results,
using 177Lu-AMBA as radioligand, were compared with
the results obtained with established bombesin radioli-
gands, 125I-Tyr4-bombesin and the universal radioligand
125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14), in the
same tissues. The investigated tissues were human cancers
expressing GRP-R (also named BB2), NMB-R (also named
BB1) or BRS-3 (also named bb3), non-neoplastic tissues
including normal pancreas and colon, and chronic pancre-
atitis. The results of this study should permit identification
of the most suitable tumour targets for clinical trials with
this radiopharmaceutical. The data may also facilitate the
interpretation of whole-body 177Lu-AMBA scans with
regard to the labelling of normal, non-neoplastic tissues.
Materials and methods
In vitro receptor autoradiography was performed in selected cancers
and non-neoplastic tissues tested in previous studies for their bombesin
receptor expression. They are listed in Table 1. Cryostat sections
(20 μM) of the tissue samples were prepared. Several radioligands
were used in parallel in these experiments. The radioligand tested was
177Lu-AMBA, radiolabelled by Bracco, Inc. [12] (Princeton, NJ) and
shipped to Switzerland. All experiments with this radioligand were
performed within 1 week after labelling. For comparison, receptor
autoradiography was also performed with other bombesin radioli-
gands, such as 125I-Tyr4-bombesin, known to preferentially label GRP
receptors [14], and the newly developed radioligand 125I-[D-Tyr6,β-
Ala11,Phe13,Nle14]-bombesin(6–14), which has been reported to be an
outstanding universal ligand that identifies all bombesin receptor
subtypes [13, 15].
For autoradiography, tissue sections were mounted on precleaned
microscope slides and stored at −20°C for at least 3 days to improve
adhesion of the tissue to the slide. The sections were first pre-incubated
in 10 mM HEPES (pH 7.4) for 5 min at room temperature. They were
then incubated in 10 mM HEPES, 130 mM NaCl, 4.7 mM KCI, 5 mM
MgCl2, 1 mM ethylene glycol-bis (β-aminoethylether)-N-N′-tetraace-
tic acid, 0.1% BSA, 100 μg/ml bacitracin (pH 7.4) and one of the
radioligands for 1 h at room temperature. 177Lu-AMBA (1.5 Ci/μmol)
was added at a concentration of 100 pM in the presence or absence of
0.05 μM AMBA. 125I-Tyr4-bombesin (2 Ci/μmol; Anawa, Wangen,
Switzerland) was added in a concentration of 100 pM in the presence
or absence of 0.1 μM bombesin. In both cases, additional sections were
incubated in the presence of increasing amounts of GRP, NMB or
somatostatin (Bachem, Bubendorf, Switzerland) to generate compe-
titive inhibition curves. The expressed bombesin receptor subtype was
further characterised in the tissues by incubation with 20 pM125I-[D-
Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14) (2 Ci/μmol; Anawa) in
the absence of any competitor peptide, as well as in the presence of
50 nM of one of the three unlabelled competitors [D-Tyr6,β-Ala11,
Phe13,Nle14]-bombesin(6–14), GRP or NMB. This protocol has been
shown to discriminate adequately between the three receptor subtypes
GRP-R, NMB-R and BRS-3 [13, 16]. After incubation, the sections
were washed four times for 2 min each in 10 mM HEPES with 0.1%
Table 1. Comparison of the incidence of in vitro detection of bombesin receptor subtypes in various human tissues using the novel
radioligand 177 Lu-AMBA and 125 I-[D-Tyr6 ,β-Ala11 ,Phe13 ,Nle14 ]-bombesin(6–14) or 125 I-Tyr4 -bombesin
Tissues No. Expressed bombesin
receptor subtype
Incidence of detection of receptor subtypes
Using 177 Lu-AMBA Using standard BN radioligandsa
GRP-R NMB-R BRS-3 GRP-R NMB-R BRS-3
Neoplasia
Mammary ca 8 GRP-R 8/8 0/8 0/8 8/8 0/8 0/8
Prostate ca 4 GRP-R 4/4 0/4 0/4 4/4 0/4 0/4
Renal cell ca 6 GRP-R 5/6 0/6 0/6 4/6 0/6 0/6
GIST 8 GRP-R 7/8 0/8 0/8 7/8 0/8 0/8
Ileal carcinoid 8 NMB-R 0/8 8/8 0/8 0/8 8/8 0/8
GIST 1 NMB-R 0/1 1/1 0/1 0/1 1/1 0/1
Bronchial carcinoid 6 BRS-3/GRP-R 2 (ld)/6 0/6 0/6 2 (ld)/6 0/6 6/6
Colon ca
Tumour 7 GRP-R 3 (ld)/7 0/7 0/7 3 (ld)/7 0/7 0/7
Smooth muscle 7 GRP-R 7/7 0/7 0/7 7/7 0/7 0/7
Pancreas ca 4 – 0/4 0/4 0/4 0/4 0/4 0/4
Peritumoural vessels around neoplasiab 6 GRP-R 6/6 0/6 0/6 6/6 0/6 0/6
Non-neoplastic tissue
Chronic pancreatitis (acini) 5 GRP-R 5/5 0/5 0/5 5/5 0/5 0/5
Human pancreas (acini) 7 – 1 (ld)/7c 0/7 0/7 0/7 0/7 0/7
Mouse pancreas (acini) 4 GRP-R 4/4 0/4 0/4 4/4 0/4 0/4
The tested tumours represent a selection of tumours characterised for bombesin receptor expression. The reported incidence therefore does
not reflect the naturally occurring incidence.
BN bombesin, ld samples with a low density of receptors
a 125 I-Tyr4 -bombesin and 125 I-[D-Tyr6 ,β-Ala11 ,Phe13 ,Nle14 ]-bombesin(6–14)
b Endometrial and pancreatic carcinomas
c We cannot completely exclude the possibility that the weak receptor positivity in this single case was due to mild chronic pancreatitis.
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BSA (pH 7.4) at 4°C. Finally, the slides were rinsed twice for 5 s each
at 4°C in HEPES without BSA. The slides were then dried under a
stream of cold air. They were placed in apposition to BiomaxMR films
(Eastman Kodak, Rochester, NY) and exposed for 2 days (177Lu) or
for 7 days (125I) in X-ray cassettes.
Results
Table 1 summarises the results. Prostatic, mammary and
renal cell carcinomas, as well as the gastrointestinal stromal
tumours (GIST), all identified as GRP-R-expressing
tumours with established bombesin radioligands, were
very well detected with in vitro receptor autoradiography
using 177Lu-AMBA. Some of the tumours with low levels of
GRP-R could still be identified with 177Lu-AMBA, while
they were not detected with 125I-Tyr4-bombesin or 125I-[D-
Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14) (Table 1), re-
flecting a slightly better sensitivity of the 177Lu-AMBA
tracer, probably owing to its higher affinity and/or its
different radioisotope.
All tumours that had been identified as NMB-R-
expressing tumours with established radioligands were
also visualised with 177Lu-AMBA. Conversely, none of the
BRS-3-expressing tumours were detected with 177Lu-
AMBA. By way of example, Fig. 1a shows a GRP-R-
Fig. 1. a Detection of GRP-R in
successive sections of a prostate
cancer by the universal bombe-
sin radioligand 125I-[D-Tyr6,
β-Ala11,Phe13,Nle14]-bombesin
(6–14) (A–D) and by 177Lu-
AMBA (E–H). A,E Autoradio-
grams showing total binding of
125I-[D-Tyr6,β-Ala11,Phe13,
Nle14]-bombesin(6–14) (A) or
177Lu-AMBA (E) in tumour
tissue (Tu). Bar=1 mm. B,F
Autoradiograms showing non-
specific binding in the presence
of 50 nM of [D-Tyr6,β-Ala11,
Phe13,Nle14]-bombesin(6–14)
(B) and AMBA (F). C,G Auto-
radiograms showing binding in
the presence of 50 nM GRP.
D,H Autoradiograms showing
binding in the presence of
50 nM NMB. Complete
displacement of each ligand in
the tumour is seen with GRP
but not with NMB. b Detection
of NMB-R in successive
sections of an ileal carcinoid by
125I-[D-Tyr6,β-Ala11,Phe13,
Nle14]-bombesin(6–14) (A–D)
and by 177Lu-AMBA (E–H).
Same legend as in a. Complete
displacement of each ligand in
the tumour is seen with NMB
but not with GRP. c Detection of
BRS-3 in successive sections
of a bronchial carcinoid by
125I-[D-Tyr6,β-Ala11,Phe13,
Nle14]-bombesin(6–14) (A–D)
but not by 177Lu-AMBA (E–H).
Same legend as in a. Complete
displacement of 125I-[D-Tyr6,
β-Ala11,Phe13,Nle14]-bombesin
(6–14) is obtained with the
universal ligand (B) but not
with GRP (C) or NMB (D).
177Lu-AMBA does not label
the tumour at all (E)
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Fig. 3. Detection of GRP-R-expressing pancreatic acini (P) in a
chronic pancreatitis by 125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin
(6–14) (A–D) and by 177Lu-AMBA (E–H). A,E Autoradiograms
showing total binding of 125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin
(6–14) (A) or 177Lu-AMBA (E) in pancreatic acini (P) or in islets (i).
Bar=1 mm. B,FAutoradiograms showing non-specific binding in the
presence of [D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14) (B) and
AMBA (F). C,G Autoradiograms showing binding in the presence of
50 nM GRP. D,H Autoradiograms showing binding in the presence of
50 nM NMB. Displacement of each ligand in the pancreatic acini is
seen with GRP but not with NMB. Note that the universal ligand,
125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14), but not 177Lu-
AMBA, also identifies the BRS-3-expressing islets (i). In the islets,
complete displacement is seen with the universal ligand only (B)
Fig. 2. 177Lu-AMBA labels very
strongly the acini of the mouse
pancreas (F–K) but not those
of the human pancreas (A–E).
A,F Haematoxylin and
eosin-stained sections.
Bars=1 mm. B,G Autoradio-
grams showing total binding of
177Lu-AMBA. Labelling is
absent in B, strong in G.
C,H Autoradiograms showing
non-specific binding (in the
presence of 50 nM AMBA).
D,I Autoradiograms showing
binding in the presence of
50 nM GRP. E,K Autoradio-
grams showing binding in the
presence of 50 nM NMB
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expressing prostate cancer labelled similarly with the
universal ligand and with 177Lu-AMBA, Fig. 1b shows an
NMB-R-expressing ileal carcinoid identified with both
tracers and Fig. 1c shows a BRS-3-positive bronchial
carcinoid strongly labelled with the universal radioligand
but not with 177Lu-AMBA. As the tested cases were all
preselected and chosen as receptor positive in the majority
of cases or as negative controls in a few selected cases, one
should not draw any conclusions about the natural
incidence of receptor expression in the various types of
tumour listed in Table 1.
Figure 2 shows that the normal human pancreas, known
to be devoid of GRP-R, is not labelled with 177Lu-AMBA,
whereas the GRP-R-expressing mouse pancreas is strongly
labelled with 177Lu-AMBA under identical experimental
conditions. Moreover, the islets of the human pancreas,
known to express BRS-3, were labelled with the universal
tracer 125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin(6–14) but
not with 177Lu-AMBA (Fig. 3). Finally, GRP-R were
detected in human pancreatic tissues that are pathologically
altered (chronic pancreatitis), indicating that GRP-R, when
present in this human tissue, can be identified under the
experimental conditions chosen in this study. In fact, 177Lu-
AMBA appears to identify these GRP-R in chronic pancre-
atitis with greater sensitivity than does 125I-Tyr4-bombesin,
as illustrated in Fig. 3.
While none of the pancreatic cancers had measurable
amounts of GRP-R with either tracer, a few colon
carcinomas showed a low density of heterogeneously
distributed GRP-R measured either with 177Lu-AMBA or
with standard tracers (Table 1). It should further be noted
that the smooth muscles of the colon express GRP-R in
vitro, in quantities reaching the density level of many GRP-
R-expressing tumours; these muscular receptors were
detected either with 177Lu-AMBA or with the established
bombesin ligands.
Figure 4 shows two complete displacement curves
for 177Lu-AMBA in the presence of various bombesin-like
compounds in a GRP-R and an NMB-R-expressing tumour,
illustrating the expected rank order of potency of analogues
for the respective receptor.
Discussion
We showed in a previous report that 175Lu-AMBA has a
very high affinity for human GRP and NMB receptors
(IC50: 0.8 and 0.9 nM, respectively) expressed in human
tissues while it has only low affinity for BRS-3 receptors
(IC50: >1,000 nM) [12]. These experiments were per-
formed with 125I-[D-Tyr6,β-Ala11,Phe13,Nle14]-bombesin
(6–14) as radiotracer and cold 175Lu-AMBA as displacer.
In the present study, we used the 177Lu-labelled AMBA as
radiotracer, which corresponds exactly to the tracer that
may be used in future for nuclear medicine purposes in
vivo in humans. We can herewith markedly extend the
preliminary data reported previously [12]: All GRP-R-
expressing human cancers were very strongly labelled with
177Lu-AMBA. The same was true for all NMB-R-positive
tumours. Conversely, tumours with BRS-3 receptors were
not visualised. The sensitivity of 177Lu-AMBA appears
slightly better than that of 125I-Tyr4-bombesin or the 125I-
labelled universal bombesin analogue, although a direct
comparison cannot be made owing to the different
radioisotopes present in the two radiopharmaceuticals. It
is to be noted that a few tumours expressing a low density
of GRP-R could be readily identified with 177Lu-AMBA
while they remained negative with 125I-Tyr4-bombesin. Of
further interest is the fact that GRP-R-positive peritumoural
vessels were readily identified with 177Lu-AMBA as well
as with standard tracers. The present study therefore
strongly suggests that 177Lu-AMBAwill be a targeting tool
for GRP-R-expressing tumour cells and for neoangiogenic
vessels simultaneously.
The binding characteristics of 177Lu-AMBA could also
be confirmed in non-neoplastic tissues. While the mouse
pancreas, as control, was shown to express a very high
density of GRP-R, the normal human pancreatic acini were
Fig. 4. Competition experiments with 177Lu-AMBA in a GRP-R-
expressing prostatic cancer (upper graph) and an NMB-R-expres-
sing ileal carcinoid (lower graph). Displacement by AMBA (●),
GRP (▲) and NMB (■). Rank order of potencies of compounds
corresponds to the expressed bombesin receptor subtype
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devoid of measurable amounts of GRP-R [17]. However, in
conditions of chronic pancreatitis, GRP-R could be
identified in acini, as reported previously [17], again with
a better sensitivity when using 177Lu-AMBA than when
using 125I-Tyr4-bombesin. Conversely, as expected, the
BRS-3-expressing islets were not detected with 177Lu-
AMBA, while these same islets were strongly labelled with
the universal ligand [17]. It should be stressed that the
normal pancreas is a very rapidly degradable tissue; it is
hardly possible to exclude degradation of proteins,
including receptor proteins, in particular in the human
pancreas, which may be resected under suboptimal
conditions. Nevertheless, that the human pancreas data
are truly negative data is indicated not only by the positive
control of the mouse pancreas tested under similar
experimental conditions but also by the strong labelling
of BRS-3 receptors in the islets of the human pancreas,
which represents a positive control for the quality of the
investigated human pancreas. While a minority of colon
carcinomas had GRP-R, usually in a very low density and
with a heterogeneous distribution, the normal colonic
smooth muscles expressed, as reported previously [18], a
high density of GRP-R, all labelled with 177Lu-AMBA.
While the GRP-R density in the smooth muscles was lower
than that in prostate cancers and lower than or comparable
to that in breast cancers and GIST, it was higher than that in
renal cell carcinomas.
This study suggests that 177Lu-AMBA is an excellent
radioligand to target GRP-R and NMB-R-expressing
human tumours, such as prostate, mammary and renal
cell carcinomas (GRP-R), gastrointestinal stromal tumours
(GRP-R) and ileal carcinoids (NMB-R), but also GRP-R-
positive peritumoural vessels. Further, this in vitro study
seems to predict the absence of significant receptor-
mediated in vivo uptake in the normal human pancreas
(in contrast to very high uptake in the mouse pancreas),
while in vivo uptake of 177Lu-AMBA may be foreseen in
chronic pancreatitis and at the level of the colonic smooth
muscles, both tissues expressing GRP-R. Based on these
promising data, the development of 177Lu-AMBA for
clinical use as a targeting agent may open exciting new
opportunities in nuclear medicine.
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